Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Commentary|Articles|February 11, 2026
Kidney Cancer Experts Preview Practice-Shaping Trials Taking Center Stage at ASCO GU 2026
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.
Advertisement
Advertisement
As anticipation builds for the
Related to this article
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
Advertisement
Advertisement